Sign In
Buy KYMR
$73.21
+1.92 (+2.69%)
At Close: Jun 03, 2026
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
12:02pm, Thursday, 15'th Dec 2022
Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
01:44pm, Wednesday, 14'th Dec 2022
Business wins are shining the spotlight on these two companies.
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
11:08am, Wednesday, 14'th Dec 2022
What's trending in the pharmaceutical sector today? In a fresh press release, Kymera Therapeutics (NASDAQ: KYMR ) disclosed positive results from its clinical trial for a skin condition treatment the
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
07:00am, Thursday, 01'st Dec 2022
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Kymera: Upcoming Trial Data Will Make Or Break The Company
11:46am, Tuesday, 08'th Nov 2022
Kymera has some critical trial data coming up this quarter. Other IRAK4 inhibitors have been having trouble.
Kymera Therapeutics, Inc. (KYMR) Q3 2022 Earnings Call Transcript
01:27am, Sunday, 06'th Nov 2022
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Nello Mainolfi - Founder & Chief Executive Officer Jared Gollob - Chief Medic
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
09:47am, Thursday, 03'rd Nov 2022
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -12.86% and 41.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
07:30am, Thursday, 20'th Oct 2022
Company also presenting at upcoming investor conferences Company also presenting at upcoming investor conferences
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock
09:15am, Wednesday, 24'th Aug 2022
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades.
Kymera Therapeutics, Inc. (KYMR) CEO Nello Mainolfi on Q2 2022 Results - Earnings Call Transcript
02:11am, Wednesday, 10'th Aug 2022
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Nello Mainolfi - Founder & CEO Jared Gollob - Chief Medical Officer Bruce Jacob
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -14.71% and 9.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
07:30am, Wednesday, 27'th Jul 2022
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small m
3 Biotech Stocks to Buy Before They Boom
06:15am, Wednesday, 01'st Jun 2022
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. The post 3 Biotech Stocks to Buy Before They Boom appeared first on
